{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-020860","form_type":"8-K","ticker":"GERN","cik":"0000886744","company_name":"GERON CORP","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.627466+00:00","generated_at":"2026-06-15T05:28:34.897271+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Geron posts Q1 net loss $38.1M; cash $409.2M; NDA on track for June 2023","bullets":["Net loss of $38.1M ($0.07/sh) vs $30.1M loss ($0.09/sh) in Q1 2022; revenue negligible.","Cash & marketable securities $409.2M; raised $213.3M from Jan 2023 offering plus $59.8M warrant exercises.","Planned U.S. NDA submission for imetelstat in lower-risk MDS on track for June 2023; potential launch H1 2024.","Reaffirmed FY2023 GAAP total expense guidance of $210M-$220M; non-GAAP $200M-$210M.","Cash runway projected through Q3 2025, supporting US/EU launches and IMpactMF Phase 3 trial."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-020860","json":"https://secwatch.observer/filing/0000950170-23-020860.json","markdown":"https://secwatch.observer/filing/0000950170-23-020860.md","text":"https://secwatch.observer/filing/0000950170-23-020860.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/886744/000095017023020860/0000950170-23-020860-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/886744/000095017023020860/gern-20230511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T05:28:34.897271+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"07db2fa9ba4256932f10843c0df5a5436d8f256f","claim":"GERON CORP reported the first quarter of 2023 results: revenue $21,000, net income $38.1 million, or $0.07 per share, EPS $0.07 per share. Guidance reaffirmed.","evidence_excerpt":"a net loss of $38.1 million, or $0.07 per share, compared to $30.1 million, or $0.09 per share, for the first quarter of 2022. Revenues for the first quarter of 2023 were $21,000 compared to $123,000 for the same period in 2022. Royalty revenues in 2023 and 2022 primarily reflect estimated royalties from sales of cell-based research products from the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/886744/000095017023020860/0000950170-23-020860-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter of 2023"},{"label":"Revenue","value":"$21,000"},{"label":"Net income","value":"$38.1 million, or $0.07 per share"},{"label":"EPS","value":"$0.07 per share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}